文献速递临床免疫分子诊断质量管理与危急值

Gasdermin蛋白作为卵巢癌焦亡相关生物标志物的诊断与预后价值

Gasdermin proteins as pyroptosis-based biomarkers in ovarian cancer: Diagnostic and prognostic utility.
PubMed 文献 · Clin Chim Acta · 2026-06-06

本文综述了gasdermin家族蛋白(尤其GSDMD、GSDME、GSDMC)作为卵巢癌焦亡相关生物标志物的潜力。文章评估了组织表达模式、循环裂解片段信号、表观遗传改变和转录组特征,并讨论了免疫组化、ELISA、定量RT-PCR及多重诊断平台等实验室检测方法,指出将gasdermin标志物与CA125、HE4等整合可提高诊断精度和生存分层。

要点

  • GSDMD和GSDMC在卵巢肿瘤组织中持续上调,GSDME呈情境依赖性低表达或激活。
  • 血清和血浆中可检测到循环裂解片段,AUC值支持其诊断价值。
  • Gasdermin标志物与CA125、HE4整合可改善诊断精度和生存分层。

核心结论

  • Gasdermin家族蛋白作为焦亡执行分子,在卵巢癌组织和液体活检标本中可检测到改变,有潜力改善诊断和预后评估。

研究设计与样本

  • 综述,讨论gasdermin基生物标志物在卵巢癌诊断和预后评估中的潜力。

主要发现

  • 在卵巢肿瘤组织中GSDMD和GSDMC持续上调,而GSDME呈情境依赖性低表达或激活。
  • 血清和血浆中可检测到循环裂解片段,AUC值支持该观察。

关键数值与推荐

  • 评估了组织表达模式、循环裂解衍生信号、表观遗传改变和转录组特征。
  • 实验室评估平台包括免疫组化、ELISA、定量RT-PCR和多重诊断方法。
  • Gasdermin相关标志物与CA125和HE4等现有标志物整合可提高诊断精度和生存分层。

临床怎么用

  • 将gasdermin基生物标志物纳入多参数诊断框架,可能支持更准确的疾病分类、改善的预后评估和更个体化的卵巢癌管理。

局限性

  • 临床转化仍需多中心分析验证、互通参考物质、外部质量评估和决策影响研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current laboratory-based diagnostic approaches for ovarian cancer have important limitations, particularly in early stage detection and clinically meaningful prognostic stratification. Widely used biomarkers, such as CA125 and HE4, can support diagnosis and disease monitoring; however, their sensitivity and specificity remain inadequate across diverse clinical settings, including the evaluation of indeterminate adnexal masses and biologically heterogeneous tumors. Consequently, increasing attention has been directed towards mechanism-based biomarkers that more closely reflect tumor biology and clinically relevant disease states. Among these, gasdermin family proteins, particularly GSDMD, GSDME, and GSDMC, have emerged as promising candidates owing to their central role as executors of pyroptosis and their measurable alterations in tumor tissues and liquid biopsy specimens of patients with cancer. In ovarian tumor tissues, GSDMD and GSDMC are consistently upregulated, whereas GSDME is under expressed or activated in a context-specific manner. Additionally, circulating cleaved fragments were detectable in the serum and plasma, with AUC values supporting this observation. In this review, we discuss the potential of gasdermin-based biomarkers for improving the diagnosis and prognostic assessment of ovarian cancer. We evaluated tissue expression patterns, circulating cleavage-derived signals, epigenetic alterations, and transcriptomic signatures, highlighting their analytical relevance and potential clinical utility. We also examined the laboratory platforms used for their evaluation, including immunohistochemistry, ELISA, quantitative RT-PCR, and multiplex diagnostic approaches, and discussed how the integration of gasdermin-related markers with established biomarkers, such as CA125 and HE, c cand improve diagnostic precision and survival stratification. Finally, we addressed the major requirements for clinical translation, including multicenter analytical validation, commutable reference materials, external quality assessments, and decision-impact studies. The incorporation of gasdermin-based biomarkers into multiparameter diagnostic frameworks could support more accurate disease classification, improved prognostic evaluation, and more individualized management of ovarian cancer.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Alruwaili MM, Alenazi MS, Mostafa HM, et al. Gasdermin proteins as pyroptosis-based biomarkers in ovarian cancer: Diagnostic and prognostic utility. Clin Chim Acta. 2026. PMID: 42251925. doi:10.1016/j.cca.2026.121152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。